Shows
GN in TenEpisode 5: Industry Perspective with Jula Inrig: Endothelin Antagonism, IgAN, FSGS, Clinical Trial Career Paths, and the New Era of Nephrology TrialsIn this episode, Kenar and Koyal talk with Dr. Jula Inrig about endothelin physiology and different approaches to endothelin antagonism, trials of sparsentan in IgAN and FSGS, the art and science of clinical trial design, career paths in clinical research outside academia, and how we got to our current era of plentiful nephrology clinical trials.Disclosure: Jula Inrig is the Chief Medical Officer of Travere Therapeutics, which is one of multiple corporate partners that provide financial support to ISGD. Dr. Inrig also serves independently on the ISGD Steering Committee as a representative of industry...2024-04-2624 min
Empowered Patient PodcastInnovation and Developments in Treating Rare Kidney Disease with Dr. Jula Inrig Travere Therapeutics TRANSCRIPTDr. Jula Inrig is the Chief Medical Officer of Travere Therapeutics and is eager to find innovative treatments for rare kidney diseases, which can be challenging to diagnose and have limited therapeutic options. In clinical trials, their lead candidate, sparsentan, reduces proteinuria significantly in patients with IgA Nephropathy and focal segmental glomerulosclerosis (FSGS). Travere is working with the U.S. Preventive Task Force to encourage earlier diagnosis and screening for these often silent diseases. Jula explains, "We've mapped out a path to get therapies approved for trying to avoid really what is one of the most detrimental...2023-01-2700 minEmpowered Patient PodcastInnovation and Developments in Treating Rare Kidney Disease with Dr. Jula Inrig Travere TherapeuticsDr. Jula Inrig is the Chief Medical Officer of Travere Therapeutics and is eager to find innovative treatments for rare kidney diseases, which can be challenging to diagnose and have limited therapeutic options. In clinical trials, their lead candidate, sparsentan, reduces proteinuria significantly in patients with IgA Nephropathy and focal segmental glomerulosclerosis (FSGS). Travere is working with the U.S. Preventive Task Force to encourage earlier diagnosis and screening for these often silent diseases. Jula explains, "We've mapped out a path to get therapies approved for trying to avoid really what is one of the most detrimental...2023-01-2716 minEmpowered Patient PodcastInnovative Treatment to Avoid Kidney Failure from Rare Kidney Diseases with Dr. Jula Inrig Travere Therapeutics TRANSCRIPTDr. Jula Inrig is the Chief Medical Officer of Travere Therapeutics and is eager to find innovative treatments for rare kidney diseases, which can be challenging to diagnose and have limited therapeutic options. In clinical trials, their lead candidate, sparsentan, reduces proteinuria significantly in patients with IgA Nephropathy and focal segmental glomerulosclerosis (FSGS), delaying kidney failure. Travere is working with the U.S. Preventive Task Force to encourage earlier diagnosis and screening for these often silent diseases. Jula explains, "We've mapped out a path to get therapies approved for trying to avoid really what is one of...2023-01-2700 minEmpowered Patient PodcastInnovative Treatment to Avoid Kidney Failure from Rare Kidney Diseases with Dr. Jula Inrig Travere TherapeuticsDr. Jula Inrig is the Chief Medical Officer of Travere Therapeutics and is eager to find innovative treatments for rare kidney diseases, which can be challenging to diagnose and have limited therapeutic options. In clinical trials, their lead candidate, sparsentan, reduces proteinuria significantly in patients with IgA Nephropathy and focal segmental glomerulosclerosis (FSGS), delaying kidney failure. Travere is working with the U.S. Preventive Task Force to encourage earlier diagnosis and screening for these often silent diseases. Jula explains, "We've mapped out a path to get therapies approved for trying to avoid really what is one of...2023-01-2716 min
ASN PodcastASN Kidney Week 2015 Day 3 PodcastASN President Jonathan Himmelfarb, MD, FASN, discusses Day 3 of Kidney Week with Dr. Neil Powe, Dr. Jula Inrig, and Dr. Wolfgang Winkelmayer. ASN Kidney Week Podcasts are supported by OPKO Renal.2015-11-0720 min